Full-Time

Research Associate

Molecular Biologist

Posted on 6/18/2024

Sana Biotechnology

Sana Biotechnology

201-500 employees

Develops engineered cell therapies for diseases

Compensation Overview

$75k - $88kAnnually

Junior, Mid

Cambridge, MA, USA

Full-time on-site work required in Cambridge, MA.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • BA/MA in cell biology or molecular biology, with an emphasis in stem cell biology or neuroscience, and at least 2 years of practical laboratory experience, whether full-time or while in training
  • Experience in flow cytometry, including sorting of cells based on fluorescent labels
  • Experience with single cell genomic assays such as 10x Genomics platforms is required
  • Excellent interpersonal, communicative, and problem-solving skills
  • Proficiency with MS Office, and with standard programs for statistical analysis (e.g., GraphPad Prism) and flow cytometry analysis and quantification (e.g., FlowJo)
  • Demonstrate the ability to act independently and with initiative, while integrating effectively into a larger team to advance shared goals.
Responsibilities
  • Perform DNA and RNA-based genomic assays, including both bulk and single cell genomic and epigenomic approaches
  • Capture and analyze cell samples – both from culture and dissected tissues - using flow cytometry, fluorescence activated cell sorting, and histological approaches
  • Establish and process sequencing libraries for transcriptomic and epigenetic analysis
  • Assure the quality, integrity, and documentation of all data collection including compliance with all relevant lab safety and biosafety regulations.

Sana Biotechnology develops engineered cells aimed at treating and potentially curing various diseases. Their approach focuses on addressing the root causes of diseases by repairing genes within cells or replacing damaged cells. This method allows for the creation of new types of medicines that can improve patient outcomes significantly. Sana's main clients include healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. The company invests heavily in research and development to discover new treatments, which they monetize through licensing agreements, partnerships, and direct sales. Unlike many competitors, Sana's focus on cellular and genetic medicine positions them uniquely in the biotechnology sector. Their goal is to create effective treatments that target genetic and cellular issues, ultimately enhancing patient care.

Company Size

201-500

Company Stage

IPO

Total Funding

$798.6M

Headquarters

Seattle, Washington

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Sana raised $189.75 million through a PIPE offering, showing strong investor confidence.
  • The new Bothell facility expands Sana's capacity for creating engineered cell medicines.
  • Fast Track designation for SC291 expedites development for high unmet need diseases.

What critics are saying

  • Increased competition from companies like BlueRock Therapeutics in regenerative medicine.
  • Resignation of key R&D figure, Dr. Douglas Williams, may disrupt innovation pipeline.
  • Opening a new facility in Bothell could strain financial and management resources.

What makes Sana Biotechnology unique

  • Sana focuses on engineered cells to treat diseases at genetic and cellular levels.
  • The company has FDA Fast Track designation for SC291 in autoimmune diseases.
  • Sana's R&D investments lead to innovative cellular therapies for unmet medical needs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

Paid Sick Leave

Paid Holidays

Disability Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Employee Stock Purchase Plan

Commuter Benefits

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

5%

2 year growth

6%
GeekWire
Feb 11th, 2025
Kestra Medical Technologies, Maker Of Wearable Cardiac Devices, Files For Ipo

Kestra Medical Technologies device for detecting and responding to cardiac events. (Kestra Photo)Kestra Medical Technologies, a Kirkland, Wash.-based company selling cardiac monitoring and therapeutic devices, filed for an initial public offering on Monday.The company’s revenue more than tripled from $7.6 million in fiscal year 2023 to $27.8 million in the last fiscal year, which ended in April. Net losses for the same periods were $84.2 million in 2023 and $94.1 million last year, according to a filing with the U.S. Securities and Exchange Commission.Monday’s filling marks the end of a long dry stretch with no traditional IPOs for Seattle-area tech companies since Sana Biotechnology went public in 2021. Companies have gone public since that time via a special purpose acquisition company (SPAC), the most recent being Longevity Biomedical in 2023. This follows a broader trend that saw a surge in U.S

GeekWire
Feb 11th, 2025
Kestra Medical Technologies, maker of wearable cardiac devices, files for IPO

Monday's filling marks the end of a long dry stretch with no traditional IPOs for Seattle-area tech companies since Sana Biotechnology went public in 2021.

GlobeNewswire
Jan 8th, 2025
Sana Biotechnology To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Wednesday, January 15, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer

GlobeNewswire
Dec 2nd, 2024
Sana Biotechnology Announces Fast Track Designation For Sc291 In Relapsed/Refractory Systemic Lupus Erythematosus

Fast Track designation is designed to expedite clinical development and regulatory review timelinesEnrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus erythematosus; expect to report initial clinical data in 2025SEATTLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for SC291 in relapsed/refractory systemic lupus erythematosus (SLE), which includes extrarenal lupus and lupus nephritis. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.SC291, a hypoimmune (HIP)-modified CD19-directed allogeneic CAR T therapy, is being evaluated in Sana’s GLEAM trial in patients with B-cell mediated autoimmune diseases including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Sana is enrolling patients in this study and expects to share initial data in 2025.“We are pleased to receive Fast Track designation from the FDA for SC291, which highlights the need for new treatment options for patients with relapsed/refractory SLE,” said Dhaval Patel, M.D., Ph.D., Chief Scientific Officer of Sana

Yahoo Finance
Aug 26th, 2024
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

Sana Biotechnology appoints accomplished drug developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer.

INACTIVE